FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380991809> ?p ?o ?g. }

• W4380991809 abstract "Pyrotinib is a novel irreversible pan-HER tyrosine kinase inhibitor (TKI). However, real-world data of pyrotinib-containing therapy in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and developing brain metastases (BMs) are limited, and the genomic profile of this subpopulation is almost undefined.Patients with BM of HER2-positive MBC (n = 35) treated with pyrotinib-containing therapy were enrolled in this analysis. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and toxicity profiles were evaluated. Hazard ratios (HRs) and 95% confidence intervals (CIs) for disease progression were estimated using the Cox proportional hazards models. Targeted next-generation sequencing of 618 cancer-relevant genes was performed on plasma and primary breast tumors from patients with BM and without BM.The median PFS time was 8.00 (95% CI, 5.98-10.017) months, and the median OS time was 23 (95% CI, 10.412-35.588) months. The ORR was 45.7%, and the DCR was 74.3%. In the Cox multivariate analysis, prior exposure to brain radiotherapy (HR = 3.268), received pyrotinib as third- or higher-line treatment (HR = 4.949), subtentorial brain metastasis (HR = 6.222), and both supratentorial and subtentorial brain metastases (HR = 5.863) were independently associated with increased risk of progression. The frequent grade 3-4 adverse event was increased direct bilirubin (14.3%), and two patients suffered from grade 3-4 diarrhea. In the exploratory genomic analysis, altered frequencies of FGFR3, CD276, CDC73, and EPHX1 were higher in the BM group. The consistency of mutated profiles of plasma and primary lesion in the BM group was significantly lower (30.4% vs. 65.5%; p = 0.0038).Pyrotinib-containing therapy shows favorable effectiveness and tolerable safety in patients with BM of HER2-positive MBC, particularly in a population that is brain radiotherapy-naïve, received pyrotinib as first- or second-line treatment, and developed supratentorial brain metastasis. In the exploratory genomic analysis, patients with BM showed distinct genomic features from patients without BM." @default.
• W4380991809 created "2023-06-17" @default.
• W4380991809 creator A5019132775 @default.
• W4380991809 creator A5021095828 @default.
• W4380991809 creator A5032336014 @default.
• W4380991809 creator A5033530580 @default.
• W4380991809 creator A5034317108 @default.
• W4380991809 creator A5037352291 @default.
• W4380991809 creator A5045036212 @default.
• W4380991809 creator A5046243607 @default.
• W4380991809 creator A5058046068 @default.
• W4380991809 creator A5058283264 @default.
• W4380991809 creator A5064215103 @default.
• W4380991809 creator A5089860286 @default.
• W4380991809 creator A5089883344 @default.
• W4380991809 creator A5090366405 @default.
• W4380991809 date "2023-06-16" @default.
• W4380991809 modified "2023-09-23" @default.
• W4380991809 title "Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits" @default.
• W4380991809 cites W1514831322 @default.
• W4380991809 cites W1976446970 @default.
• W4380991809 cites W1992140459 @default.
• W4380991809 cites W1997480652 @default.
• W4380991809 cites W1998694514 @default.
• W4380991809 cites W2004936781 @default.
• W4380991809 cites W2009776759 @default.
• W4380991809 cites W2045134790 @default.
• W4380991809 cites W2062352315 @default.
• W4380991809 cites W2084850405 @default.
• W4380991809 cites W2088255940 @default.
• W4380991809 cites W2095783009 @default.
• W4380991809 cites W2096867589 @default.
• W4380991809 cites W2101824720 @default.
• W4380991809 cites W2104418558 @default.
• W4380991809 cites W2116760308 @default.
• W4380991809 cites W2119997685 @default.
• W4380991809 cites W2125401809 @default.
• W4380991809 cites W2127714076 @default.
• W4380991809 cites W2130735457 @default.
• W4380991809 cites W2138253215 @default.
• W4380991809 cites W2143184226 @default.
• W4380991809 cites W2149550866 @default.
• W4380991809 cites W2159967578 @default.
• W4380991809 cites W2161574596 @default.
• W4380991809 cites W2168814163 @default.
• W4380991809 cites W2175940415 @default.
• W4380991809 cites W2314772071 @default.
• W4380991809 cites W2373239564 @default.
• W4380991809 cites W2491147657 @default.
• W4380991809 cites W2529180577 @default.
• W4380991809 cites W2560396529 @default.
• W4380991809 cites W2577651608 @default.
• W4380991809 cites W2613098450 @default.
• W4380991809 cites W2764128275 @default.
• W4380991809 cites W2911053766 @default.
• W4380991809 cites W2921590809 @default.
• W4380991809 cites W2945430316 @default.
• W4380991809 cites W2969604985 @default.
• W4380991809 cites W2997617470 @default.
• W4380991809 cites W3030461309 @default.
• W4380991809 cites W3039853672 @default.
• W4380991809 cites W3044204256 @default.
• W4380991809 cites W3083176429 @default.
• W4380991809 cites W3115960961 @default.
• W4380991809 cites W3127064904 @default.
• W4380991809 cites W3157950444 @default.
• W4380991809 cites W3168333147 @default.
• W4380991809 cites W3169646530 @default.
• W4380991809 cites W4200190043 @default.
• W4380991809 cites W4200453601 @default.
• W4380991809 cites W4206510797 @default.
• W4380991809 cites W4210581512 @default.
• W4380991809 cites W4220685273 @default.
• W4380991809 cites W4281761766 @default.
• W4380991809 cites W4281786463 @default.
• W4380991809 cites W4283216169 @default.
• W4380991809 cites W4290673816 @default.
• W4380991809 cites W4306361728 @default.
• W4380991809 cites W4306702005 @default.
• W4380991809 cites W4307656952 @default.
• W4380991809 cites W4328112200 @default.
• W4380991809 doi "https://doi.org/10.3389/fonc.2023.1105474" @default.
• W4380991809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37397372" @default.
• W4380991809 hasPublicationYear "2023" @default.
• W4380991809 type Work @default.
• W4380991809 citedByCount "0" @default.
• W4380991809 crossrefType "journal-article" @default.
• W4380991809 hasAuthorship W4380991809A5019132775 @default.
• W4380991809 hasAuthorship W4380991809A5021095828 @default.
• W4380991809 hasAuthorship W4380991809A5032336014 @default.
• W4380991809 hasAuthorship W4380991809A5033530580 @default.
• W4380991809 hasAuthorship W4380991809A5034317108 @default.
• W4380991809 hasAuthorship W4380991809A5037352291 @default.
• W4380991809 hasAuthorship W4380991809A5045036212 @default.
• W4380991809 hasAuthorship W4380991809A5046243607 @default.
• W4380991809 hasAuthorship W4380991809A5058046068 @default.
• W4380991809 hasAuthorship W4380991809A5058283264 @default.
• W4380991809 hasAuthorship W4380991809A5064215103 @default.
• W4380991809 hasAuthorship W4380991809A5089860286 @default.
• W4380991809 hasAuthorship W4380991809A5089883344 @default.

• next